InvestorsHub Logo
Followers 11
Posts 1326
Boards Moderated 0
Alias Born 07/07/2009

Re: None

Saturday, 10/07/2017 7:57:42 AM

Saturday, October 07, 2017 7:57:42 AM

Post# of 6411
Nexavar has been extremely succesfull in treating the intended conditions and is currently generating approximately $1.5 Billion in annual sales. The patent for the drug is expiring in 2017.

Nexavar`s combination w VGLS`s patented MDT compound becomes very valuable to Bayer`s as it extends the life of Nexavar, maintaining its key role in Bayer`s revenue stream and new drug pipeline.

In addition, VGLS is currently working on the following projects in collaboration with some of the nation`s leading universities: